A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models

IntroductionNon-small cell lung cancer (NSCLC) patients who do not respond to standard of care treatment can have activating mutations in the epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (cMET) signaling pathways, as well as having enhanced levels of vascular...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Jin, Ping Sun, Peng Chen, Yuqiang Xu, Guangmao Mu, Zhengxia Zha, Simin Wu, Meixia Fu, Hao Jiang, Sheng Huang, Fulai Zhou, Chao Han, Mark L. Chiu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Oncology
Subjects:
trispecific antibodies
NSCLC
EGFR cancer cells +
cmet
VEGF
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1533059/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1533059/full

Similar Items